Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, Huerta M, Roselló S, Martinez-Ciarpaglini C, Carbonell-Asins JA, Carrasco F, Ferrer-Martínez A, Bruixola G, Fleitas T, Martín J, Tébar-Martínez R, Moro D, Castillo J, Espí A, Roda D, Cervantes A. Tarazona N, et al. Among authors: rosello s. Ann Oncol. 2019 Nov 1;30(11):1804-1812. doi: 10.1093/annonc/mdz390. Ann Oncol. 2019. PMID: 31562764 Free article.
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial.
Martín-Martorell P, Roselló S, Rodríguez-Braun E, Chirivella I, Bosch A, Cervantes A. Martín-Martorell P, et al. Among authors: rosello s. Br J Cancer. 2008 Aug 5;99(3):455-8. doi: 10.1038/sj.bjc.6604530. Br J Cancer. 2008. PMID: 18665167 Free PMC article. Clinical Trial.
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.
Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Roselló S, Liebscher S, Kisker O, Macarulla T, Baselga J, Cervantes A. Tabernero J, et al. Among authors: rosello s. Ann Oncol. 2010 Jul;21(7):1537-1545. doi: 10.1093/annonc/mdp549. Epub 2009 Nov 25. Ann Oncol. 2010. PMID: 19940007 Free article. Clinical Trial.
Current questions for the treatment of advanced gastric cancer.
Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA. Cervantes A, et al. Among authors: rosello s. Cancer Treat Rev. 2013 Feb;39(1):60-7. doi: 10.1016/j.ctrv.2012.09.007. Epub 2012 Oct 25. Cancer Treat Rev. 2013. PMID: 23102520 Review.
Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment.
Martínez MT, González I, Tarazona N, Roselló S, Saiz R, Sanmartín A, Martínez-Agulló Á, Caballero A, Mas P, Franco J, Martínez-Jabaloyas J, García-Callejo J, Martín V, Navarro J, Teruel A, Lluch A, Chirivella I. Martínez MT, et al. Among authors: rosello s. Clin Transl Oncol. 2015 Feb;17(2):167-72. doi: 10.1007/s12094-014-1209-3. Epub 2014 Aug 7. Clin Transl Oncol. 2015. PMID: 25100066
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F. Macarulla T, et al. Among authors: rosello s. Br J Cancer. 2015 Jun 9;112(12):1874-81. doi: 10.1038/bjc.2015.144. Epub 2015 May 19. Br J Cancer. 2015. PMID: 25989270 Free PMC article. Clinical Trial.
117 results